ストックスクリーナーアプリを入手
85.97
3.26%
2.7943
前日終値:
$83.18
開ける：
$84.42
24時間の取引高:
1.87M
Relative Volume:
1.03
時価総額：
$14.21B
収益：
$1.06B
当期純損益:
$-326.58M
株価収益率:
-40.90
EPS:
-2.1022
ネットキャッシュフロー:
$-977.73M
1週間 パフォーマンス:
+8.32%
1か月 パフォーマンス:
+15.32%
6か月 パフォーマンス:
+3.27%
1年 パフォーマンス:
+105.58%
1日の値動き範囲:
$82.95
$86.67
1週間の範囲:
$77.95
$86.67
52週間の値動き範囲:
$40.03
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
名前
Ionis Pharmaceuticals Inc
セクター
電話
(760) 931-9200
住所
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
85.97 | 13.75B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
522.41 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.94 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.98 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.97 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | 開始されました | Canaccord Genuity | Buy |
| 2026-04-10 | 再開されました | Raymond James | Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-10-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-09-26 | アップグレード | Goldman | Sell → Neutral |
| 2025-09-03 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | アップグレード | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Neutral |
| 2024-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 再開されました | Jefferies | Buy |
| 2024-06-14 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-10-23 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 開始されました | Raymond James | Strong Buy |
| 2023-07-31 | アップグレード | Citigroup | Neutral → Buy |
| 2023-06-07 | 再開されました | Piper Sandler | Overweight |
| 2023-05-04 | アップグレード | Citigroup | Sell → Neutral |
| 2023-03-21 | 開始されました | Bernstein | Underperform |
| 2022-12-21 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 再開されました | Morgan Stanley | Overweight |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2022-03-31 | 再開されました | Piper Sandler | Overweight |
| 2022-03-01 | 開始されました | Citigroup | Sell |
| 2022-03-01 | 開始されました | Guggenheim | Buy |
| 2022-02-01 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-12-14 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | アップグレード | UBS | Sell → Neutral |
| 2021-03-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 開始されました | UBS | Sell |
| 2020-12-15 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-09-14 | 再開されました | JP Morgan | Neutral |
| 2020-09-02 | 開始されました | The Benchmark Company | Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-12-13 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-11-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 繰り返されました | Stifel | Hold |
| 2018-08-07 | 繰り返されました | Stifel | Hold |
| 2018-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 再開されました | Goldman | Sell |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-08-09 | 繰り返されました | Stifel | Hold |
| 2017-03-10 | ダウングレード | Goldman | Neutral → Sell |
| 2016-12-28 | 繰り返されました | BMO Capital Markets | Outperform |
| 2016-12-27 | 繰り返されました | Leerink Partners | Mkt Perform |
すべてを表示
Ionis Pharmaceuticals Inc (IONS) 最新ニュース
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
Ionis Pharmaceuticals concludes REVEAL study pivotal cohort enrolment - Clinical Trials Arena
Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com
Ionis Pharmaceuticals director Joseph Klein III sells $910k in stock - Investing.com Canada
Form 4 Ionis Pharmaceuticals Inc For: 6 July By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Advances Obudanersen for Angelman Syndrome - GuruFocus
Ionis Pharmaceuticals, Inc. Completes Enrollment in Pivotal Cohort of Phase 3 REVEAL Study Evaluating Obudanersen in Angelman Syndrome - marketscreener.com
Ionis Pharmaceuticals (IONS) Advances Phase 3 REVEAL Study for A - GuruFocus
Ionis completes enrollment in Angelman syndrome drug trial By Investing.com - Investing.com Canada
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome - Business Wire
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 29.48% Potential Upside in the Biotech Sphere - DirectorsTalk Interviews
IONS out-licenses ex-US rights for rare neurology drug to Recordati - MSN
IONS News | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
TimesSquare Mid Cap Growth Strategy Picks Ionis Pharmaceuticals (IONS) on Clinical Momentum - Yahoo Finance
Form 144 IONIS PHARMACEUTICALS INC For: 1 July By Investing.com - Investing.com Canada
IONSIonis Pharmaceuticals Inc Latest SEC Filings - Finviz
Ionis Pharmaceuticals EVP Schneider sells $2.1m in stock - Investing.com UK
Ionis Pharmaceuticals EVP Joseph Baroldi’s spouse sells $451,698 stock - Investing.com UK
Ionis Pharmaceuticals EVP Joseph Baroldi’s spouse sells $451,698 stock By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals EVP Schneider sells $2.1m in stock By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Trump's push for the world's lowest drug prices hits snag with mid-sized companies - marketscreener.com
Ionis Pharmaceuticals (IONS) Signs Recordati Deal For Zilganersen Outside The U.S. - Yahoo Finance
Why Ionis Pharmaceuticals (IONS) Is Up 9.5% After Dual TRYNGOLZA Approval and Zilganersen Out-Licensing Deal - Sahm
Ionis Pharmaceuticals (IONS) Is Up 9.5% After FDA Expands Tryngolza Label For Severe Hypertriglyceridemia - Yahoo Finance
Price to book forward of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS - TradingView
Enterprise value to EBITDA forward of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS - TradingView
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Insider Sell: Brett Monia Sells 85,637 Shares of Ionis Pharmaceu - GuruFocus
Form 144 IONIS PHARMACEUTICALS INC For: 26 June - Investing.com UK
Ionis (IONS) Wins Tryngolza Approval And Recordati Deal For Zilganersen - Sahm
Ionis CEO Brett Monia sells $6.8 million in company shares By Investing.com - Investing.com Nigeria
Price to earnings forward of Ionis Pharmaceuticals, Inc. – SWB:ISI - TradingView
Enterprise value to revenue forward of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS - TradingView
(IONS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Form 144 IONIS PHARMACEUTICALS INC For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of Ionis Pharmaceuticals, Inc. – SWB:ISI - TradingView
Ionis Pharmaceuticals EVP research Eric Swayze sells $839k in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP research Eric Swayze sells $839k in stock - Investing.com Australia
Form 4 Ionis Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
Ionis CEO Brett Monia sells $6.8 million in company shares - Investing.com
Ionis Pharmaceuticals, Inc. Actuals & Estimates (HAM:ISI) - TradingView
Ionis Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:IONS) - TradingView
Form 144 | Ionis Pharmaceuticals(IONS.US) Officer Proposes to Sell 3.88 Million in Common Stocks - Moomoo
Ionis Pharmaceuticals, Inc. Actuals & Estimates (DUS:ISI) - TradingView
Ionis Pharmaceuticals(IONS.US) Officer Sells US$6.83 Million in Common Stock - Moomoo
Ionis Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Ionis Pharmaceuticals (NASDAQ:IONS) Deal Sharpens Rare-Disease Focus - Kalkine Media
Barclays Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $115 - Moomoo
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati - Yahoo Finance
Ionis Pharmaceuticals, Inc. Actuals & Estimates (LSE:0JDI) - TradingView
Ionis Pharmaceuticals Inc (IONS) 財務データ
収益
当期純利益
現金流量
EPS
Ionis Pharmaceuticals Inc (IONS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| KLEIN JOSEPH III | Director |
Jul 01 '26 |
Sale |
79.04 |
11,518 |
910,416 |
11,014 |
1.21%
3.14%
大文字化:
|
ボリューム (24 時間):